February 27, 2015 7:56 PM ET


Company Overview of MORPHOTEK INC.

Company Overview

MORPHOTEK INC. develops a pipeline of preclinical and clinical stage monoclonal antibodies to treat cancer, inflammation, and infectious diseases. Its pipeline of products include Farletuzumab, an investigational monoclonal antibody that targets folate receptor alpha; Amatuximab, an monoclonal antibody that targets mesothelin; MORAb-004, an investigational monoclonal antibody that targets endosialin, MORAb-022, an investigational monoclonal antibody that targets a proinflammatory; and MORAb-066, an investigational monoclonal antibody that targets tissue factor. The company’s products are used to treat ovarian cancer, nonsmall cell lung cancer, melanoma, colorectal carcinoma, sarcoma, mesothe...

210 Welsh Pool Road

Exton, PA 19341

United States

Founded in 1999





Key Executives for MORPHOTEK INC.

Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Senior Vice President of Research & Development
Chief Finance Officer and Vice President of Project Management
Executive Director of Marketing and Executive Director of Business Development
Vice President of Pilot Plant Operations
Compensation as of Fiscal Year 2014.

MORPHOTEK INC. Key Developments

MORPHOTEK INC. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

MORPHOTEK INC. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Stealth Biologics Announces Research Collaboration with Morphotek

Stealth Biologics LLC has announced a research collaboration with Morphotek, Inc. Under terms of the agreement, Stealth Biologics will use its protein design and optimization algorithms to engineer deimmunized biologics for application in cancer therapy. Morphotek will retain the right to develop and commercialize all deimmunized therapeutics resulting from the collaboration.

Morphotek, Inc. Announces Enrollment in Phase I Solid Tumor Study

Morphotek, Inc. has opened enrollment in a Phase I clinical study with MORAb-004 in pediatric patients with relapsed/refractory solid tumors. The open-label Phase I study will assess the safety, tolerability and pharmacokinetics of MORAb-004 administered in weekly intravenous infusions in pediatric patients. MORAb-004 is an investigational monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1). The target is found to be expressed on the cell surface of cells called pericytes that are part of the tumor blood vessel architecture, as well as on fibroblast cells that are part of the tumor stroma. Morphotek obtained exclusive worldwide rights to develop and commercialize this antibody from the Ludwig Institute for Cancer Research (LICR).

Similar Private Companies By Industry

Company Name Region
Callida Genomics, Inc. United States
Genteric, Inc. United States
Mystic Pharmaceuticals, Inc. United States
EY Laboratories, Inc. United States
Kinexum Metabolics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOTEK INC., please visit www.morphotek.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.